NASDAQ:CBIO Catalyst Biosciences (CBIO) Stock Forecast, Price & News $0.23 +0.01 (+3.14%) (As of 12:06 PM ET) Add Compare Share Share Today's Range$0.22▼$0.2450-Day Range$0.19▼$0.2452-Week Range$0.19▼$2.09Volume112,293 shsAverage Volume978,402 shsMarket Capitalization$8.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalyst Biosciences MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.29% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.62Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.16) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.63 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Catalyst Biosciences. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.29% of the float of Catalyst Biosciences has been sold short.Short Interest Ratio / Days to CoverCatalyst Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Catalyst Biosciences has recently increased by 52.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Biosciences does not currently pay a dividend.Dividend GrowthCatalyst Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Biosciences has received a 56.82% net impact score from Upright. Catalyst Biosciences seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Taxes". The positive contribution in the "Physical diseases" impact category is driven by its "Preclinical research services for physical health" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Biosciences is -0.59. Previous Next 3.1 News and Social Media Coverage News SentimentCatalyst Biosciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Catalyst Biosciences this week, compared to 1 article on an average week.Search Interest6 people have searched for CBIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Catalyst Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Catalyst Biosciences is held by insiders.Percentage Held by InstitutionsOnly 35.98% of the stock of Catalyst Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Catalyst Biosciences are expected to grow in the coming year, from ($0.16) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Biosciences is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Biosciences is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Catalyst Biosciences (NASDAQ:CBIO) StockCatalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.Read More Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CBIO Stock News HeadlinesMay 29, 2023 | americanbankingnews.comShort Interest in Catalyst Biosciences, Inc. (NASDAQ:CBIO) Rises By 52.3%May 14, 2023 | americanbankingnews.comCatalyst Biosciences, Inc. (NASDAQ:CBIO) Short Interest Down 16.0% in AprilJune 1, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.April 28, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHBI, CBIO, TA, ASRTApril 27, 2023 | americanbankingnews.comCatalyst Biosciences, Inc. (NASDAQ:CBIO) Sees Large Growth in Short InterestApril 3, 2023 | finance.yahoo.comCatalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 monthsMarch 31, 2023 | insidermonkey.com5 Cheap Healthcare Stocks to Buy in 2023March 31, 2023 | markets.businessinsider.comRaymond James Sticks to Its Hold Rating for Catalyst Biosciences (CBIO)June 1, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.March 29, 2023 | finance.yahoo.com12 Cheap Healthcare Stocks to Buy in 2023March 28, 2023 | americanbankingnews.comCatalyst Biosciences (CBIO) Set to Announce Quarterly Earnings on WednesdayMarch 28, 2023 | americanbankingnews.comCatalyst Biosciences (CBIO) Set to Announce Earnings on WednesdayMarch 28, 2023 | americanbankingnews.comCatalyst Biosciences, Inc. (NASDAQ:CBIO) Sees Significant Growth in Short InterestMarch 9, 2023 | prnewswire.comCATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIOFebruary 28, 2023 | msn.comCatalyst Biosciences Shares Are Rallying: What's Driving The Action?February 28, 2023 | finance.yahoo.comCatalyst Biosciences Provides Corporate UpdateFebruary 27, 2023 | finance.yahoo.comGC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in HematologyFebruary 5, 2023 | morningstar.comCatalyst/Millburn Hedge Strategy IJanuary 19, 2023 | insidermonkey.com5 Stocks with the Lowest PE RatioJanuary 4, 2023 | prnewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Catalyst Biosciences, Inc. - CBIODecember 29, 2022 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Catalyst Biosciences, Inc. MergerDecember 29, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, BLI, ISO, CBIODecember 28, 2022 | benzinga.comCBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to ShareholdersNovember 16, 2022 | finance.yahoo.comCatalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)October 7, 2022 | fool.comHow Much Could This Catalyst Boost Shiba Inu in October?September 24, 2022 | seekingalpha.comCBIO Catalyst Biosciences, Inc.September 1, 2022 | finance.yahoo.comCatalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per shareSee More Headlines CBIO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CBIO Company Calendar Last Earnings11/12/2021Today6/01/2023Next Earnings (Estimated)6/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CBIO CUSIP87611R30 CIK1124105 Webwww.catalystbiosciences.com Phone(650) 871-0761Fax336-480-2107Employees56Year Founded2003Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,240,000.00 Net MarginsN/A Pretax Margin-994.21% Return on Equity-333.52% Return on Assets-125.48% Debt Debt-to-Equity RatioN/A Current Ratio2.05 Quick Ratio2.05 Sales & Book Value Annual Sales$790,000.00 Price / Sales11.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / Book-0.33Miscellaneous Outstanding Shares37,760,000Free Float36,250,000Market Cap$8.69 million OptionableOptionable Beta0.90 Social Links Key ExecutivesNassim UsmanPresident, Chief Executive Officer & DirectorSeline E. MillerChief Financial & Accounting OfficerTom KnudsenSenior Vice President-Strategy & DevelopmentTrisha ColtonHead-Investor RelationsKey CompetitorsInfinity PharmaceuticalsNASDAQ:INFIMolecular TemplatesNASDAQ:MTEMRegulus TherapeuticsNASDAQ:RGLSCan-Fite BioPharmaNYSE:CANFRedHill BiopharmaNASDAQ:RDHLView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 311,100 shares on 5/12/2023Ownership: 2.320%Acadian Asset Management LLCBought 259,467 shares on 5/11/2023Ownership: 0.687%Simplex Trading LLCBought 400 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions CBIO Stock - Frequently Asked Questions How have CBIO shares performed in 2023? Catalyst Biosciences' stock was trading at $0.5275 at the beginning of the year. Since then, CBIO stock has decreased by 56.4% and is now trading at $0.2301. View the best growth stocks for 2023 here. Are investors shorting Catalyst Biosciences? Catalyst Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 322,400 shares, an increase of 52.3% from the April 30th total of 211,700 shares. Based on an average trading volume of 901,400 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.3% of the shares of the company are sold short. View Catalyst Biosciences' Short Interest. When is Catalyst Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 5th 2023. View our CBIO earnings forecast. How were Catalyst Biosciences' earnings last quarter? Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced its quarterly earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.14. The biopharmaceutical company earned $2.30 million during the quarter, compared to the consensus estimate of $1 million. How often does Catalyst Biosciences pay dividends? What is the dividend yield for Catalyst Biosciences? Catalyst Biosciences declared a dividend on Wednesday, January 4th. Investors of record on Monday, January 16th will be paid a dividend of $0.24 per share on Thursday, January 12th. This represents a yield of 285.47%. The ex-dividend date of this dividend is Friday, January 13th. Read our dividend analysis for CBIO. When did Catalyst Biosciences' stock split? Shares of Catalyst Biosciences reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Catalyst Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN). What is Catalyst Biosciences' stock symbol? Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO." Who are Catalyst Biosciences' major shareholders? Catalyst Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.32%), Acadian Asset Management LLC (0.69%) and Simplex Trading LLC (0.00%). View institutional ownership trends. How do I buy shares of Catalyst Biosciences? Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalyst Biosciences' stock price today? One share of CBIO stock can currently be purchased for approximately $0.23. How much money does Catalyst Biosciences make? Catalyst Biosciences (NASDAQ:CBIO) has a market capitalization of $8.69 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-8,240,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. How can I contact Catalyst Biosciences? Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.catalystbiosciences.com. The biopharmaceutical company can be reached via phone at (650) 871-0761, via email at investors@catbio.com, or via fax at 336-480-2107. This page (NASDAQ:CBIO) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.